Abstract:Background Common genetic variants that regulate gene expression are widely suspected to contribute to the etiology and phenotypic variability of complex diseases. Although high-throughput, microarray-based assays have been developed to measure differences in mRNA expression among independent samples, these assays often lack the sensitivity to detect rare mRNAs and the reproducibility to quantify small changes in mRNA expression. By contrast, PCR-based allelic expression imbalance (AEI) assays, which use a "marker" single nucleotide polymorphism (mSNP) in the mRNA to distinguish expression from pairs of genetic alleles in individual samples, have high sensitivity and accuracy, allowing differences in mRNA expression greater than 1.2-fold to be quantified with high reproducibility. In this paper, we describe the use of an efficient PCR/next-generation DNA sequencing-based assay to analyze allele-specific differences in mRNA expression for candidate neuropsychiatric disorder genes in human brain. Results Using our assay, we successfully analyzed AEI for 70 candidate neuropsychiatric disorder genes in 52 independent human brain samples. Among these genes, 62/70 (89%) showed AEI ratios greater than 1 ± 0.2 in at least one sample and 8/70 (11%) showed no AEI. Arranging log 2 AEI ratios in increasing order from negative-to-positive values revealed highly reproducible distributions of log 2 AEI ratios that are distinct for each gene/marker SNP combination. Mathematical modeling suggests that these log 2 AEI distributions can provide important clues concerning the number, location and contributions of cis -acting regulatory variants to mRNA expression. Conclusions We have developed a highly sensitive and reproducible method for quantifying AEI of mRNA expressed in human brain. Importantly, this assay allowed quantification of differential mRNA expression for many candidate disease genes entirely missed in previously published microarray-based studies of mRNA expression in human brain. Given the ability of next-generation sequencing technology to generate large numbers of independent sequencing reads, our method should be suitable for analyzing from 100- to 200-candidate genes in 100 samples in a single experiment. We believe that this is the appropriate scale for investigating variation in mRNA expression for defined sets candidate disorder genes, allowing, for example, comprehensive coverage of genes that function within biological pathways implicated in specific disorders. The combination of AEI measurements and mathematical modeling described in this study can assist in identifying SNPs that correlate with mRNA expression. Alleles of these SNPs (individually or as sets) that accurately predict high- or low-mRNA expression should be useful as markers in genetic association studies aimed at linking candidate genes to specific neuropsychiatric disorders.

Massively parallel reporter assays and mouse transgenic assays provide complementary information about neuronal enhancer activity

Characterization of enhancer activity in early human neurodevelopment using Massively Parallel Reporter Assay (MPRA) and forebrain organoids

Enhancers Active in Dopamine Neurons Are a Primary Link Between Genetic Variation and Neuropsychiatric Disease.

Mapping cis -regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genes

Bridging between Mouse and Human Enhancer-Promoter Long-Range Interactions in Neural Stem Cells, to Understand Enhancer Function in Neurodevelopmental Disease

cis-Regulatory Chromatin Contacts in Neural Cells Reveal Contributions of Genetic Variants to Complex Neurological Disorders

Validation of Enhancer Regions in Primary Human Neural Progenitor Cells using Capture STARR-seq

MPRAnalyze: Statistical Framework for Massively Parallel Reporter Assays

A Massively Parallel CRISPR-Based Screening Platform for Modifiers of Neuronal Activity

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Next-generation DNA sequencing-based assay for measuring allelic expression imbalance (AEI) of candidate neuropsychiatric disorder genes in human brain

Systematic Dissection and Optimization of Inducible Enhancers in Human Cells Using a Massively Parallel Reporter Assay

Integrative analyses highlight functional regulatory variants associated with neuropsychiatric diseases

Using a comprehensive atlas and predictive models to reveal the complexity and evolution of brain-active regulatory elements

BRAIN-MAGNET: A novel functional genomics atlas coupled with convolutional neural networks facilitates clinical interpretation of disease relevant variants in non-coding regulatory elements

High-throughput single-cell functional elucidation of neurodevelopmental disease-associated genes reveals convergent mechanisms altering neuronal differentiation

Identification of 27 allele-specific regulatory variants in Parkinson’s disease using a massively parallel reporter assay

Genome-scale High-Resolution Mapping of Activating and Repressive Nucleotides in Regulatory Regions

Network Analysis of Enhancer-Promoter Interactions Highlights Cell-Type-Specific Mechanisms of Transcriptional Regulation Variation

High-throughput CRISPRi and CRISPRa technologies in 3D genome regulation for neuropsychiatric diseases

Integrated multiplexed assays of variant effect reveal determinants of catechol-O-methyltransferase gene expression